Abstract:The goal of this in silico and lab-based experimental study was to explore a possible role for N6-methyladenosine (m6A) in adenomyosis. Through bioinformatic analysis of the data from Gene Expression Omnibus (GEO) database, we investigated the role of m6A methylation regulators in the pathogenesis of adenomyosis. Then human samples were used to validate the results of in silico analysis. Gene expression profiles of both the endometrium and myometrium of women with and without adenomyosis were obtained from the publicly available GEO database separately. The expression, co-expression and possible target genes of the 16 m6A methylation regulators were investigated using bioinformatic analysis such as Wilcox test, Spearman correlation and WGCNA. Finally, the total m6A content, expression of m6A methylation regulators and possible target genes of m6A regulators were validated using qRT-PCR in both the endometrium and myometrium of adenomyosis women and controls. The clinical samples were collected from the Endometrial Tissue and DNA Bank at UCSF (IRB # 10-02786). In the endometrium, STRING database analysis revealed that METTL3 functions as a “hub” gene of m6A methylation regulators, and the genes involved in m6A regulation, including METTL3, FTO, ZC3H13 and YTHDC1 expression, were significantly decreased in cases versus controls. Functional, co-expression and correlational analyses of endometrium from cases versus controls revealed decreased total m6A levels, induced by METTL3, and the downstream elevated insulin-like growth factor-1(IGF1) and D-Dopachrome Tautomerase (DDT), with the latter two having known functions in epithelial proliferation and cell migration, which are important processes in the pathogenesis of adenomyosis in endometrium. M6A methylation regulators, including RBM15/15B, ALKBH5, FTO, YTHDF1/2, KIAA1429, HNRNPC, METTL3, ZC3H13 and YTHDC2, were also differentially expressed in the myometrium from cases versus controls. We validated decreased total m6A levels and differential expression of m6A methylation regulators using qRT-PCR and tissues available from our biorepository. Possible target genes, including cadherin 3(CDH), sodium channel β-subunit 4 (SCN4B) and placenta-specific protein 8 (PLAC8), which are involved in cell adhesion, muscle contraction and immune response in the myometrium of adenomyosis patients were also validate. Thus, through extensive public database mining and validation of select genes with qRT-PCR, this study, for the first time, implicates m6A and its methylation regulators in the pathogenesis of adenomyosis. Decreased METTL3 and total m6A levels in endometrium of adenomyosis patients may contribute to cell proliferation and invasion through IGF1 and DDT. Furthermore, in the myometrium, m6A methylation regulators work as a cluster and play roles in cell adhesion, muscle contraction and immune response. In conclusion, m6A methylation regulators may be involved the pathogenesis of adenomyosis through aberrant expression and actions in both the uterine endometrium and myometrium.

Data mining analysis of the prognostic impact of N 6 -methyladenosine regulators in patients with endometrial adenocarcinoma

Data Mining Analysis of the Prognostic Impact of N6-methyladenosine Regulators in Patients with Endometrial Adenocarcinoma

Effects of M6a RNA Methylation Regulators on Endometrial Cancer.

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma

Expression and Prognostic Characteristics of m<SUP>6</SUP> A RNA Methylation Regulators in Breast Cancer

M6a METHYLATION REGULATORS CONTRIBUTE TO THE EUTOPIC ENDOMETRIUM AND MYOMETRIUM DYSFUNCTION IN ADENOMYOSIS

Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer

Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers

Comprehensive analysis of m6A regulators prognostic value in prostate cancer

Identification of an Eight-M6a RNA Methylation Regulator Prognostic Signature of Uterine Corpus Endometrial Carcinoma Based on Bioinformatics Analysis

Prognostic Implication of the m6A RNA Methylation Regulators in Rectal Cancer

Genomics and Prognosis Analysis of N6-Methyladenosine Regulators in Lung Adenocarcinoma

Systematic Analysis of Tumor Microenvironment Patterns and Oxidative Stress Characteristics of Endometrial Carcinoma Mediated by 5-Methylcytosine Regulators

Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma

Expression Patterns and Prognostic Value of M6a RNA Methylation Regulators in Adrenocortical Carcinoma.

Exploration Of The Role Of M(6) A Rna Methylation Regulators In Malignant Progression And Clinical Prognosis Of Ovarian Cancer

Exploring Diagnostic M6a Regulators in Endometriosis.

N 6 -methyladenosine demethyltransferase FTO mediated m 6 A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis

N6-methyladenosine-related Genes Contribute to Malignant Progression, Have Clinical Prognostic and Neoadjuvant Treatments Response Impact for Breast Cancer

Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers